Nervous Disorder TRIZ Cases

Tartaric acid resolves racemic milnacipran into diastereomeric salts, achieving optical purity above 99.0% without complex asymmetric synthesis.

Boron-containing compounds inhibit arginase enzymes, restoring nitric oxide and polyamine levels to treat pulmonary hypertension.

Intracranial administration of polyclonal activated T cells reduces amyloid burden and enhances neurogenesis without triggering meningoencephalitis.

Replacing sodium tert-butoxide with potassium tert-butoxide minimizes by-products, eliminating column chromatography and simplifying industrial purification.

Cell-derived nanovesicles transport oligonucleotide inhibitors to cancer cells, reducing systemic side effects.

A blended composition of Uncaria tomentosa and Oolong tea extract inhibits tau fibril formation and dissolves preformed protein aggregates.

FcγRIIb inhibitors block amyloid-beta binding to resolve marginal treatment effectiveness and neurotoxicity in Alzheimer's disease.

A sumatriptan salt composition uses an alkyl glycoside permeation enhancer to accelerate drug absorption across the nasal mucosa.

A pharmaceutical composition uses benzyl alcohol and polyoxyethylene derivatives to form a flocculated suspension of water-insoluble antipsychotic agents.

Administering psychedelic compounds reopens the critical window for motor skill relearning, resolving limited improvement when neuroplasticity decreases.

Guggulsterone and kenpaullone inhibit GSK-3β and iNOS to reduce nitric oxide levels, addressing progressive dopamine neuron degeneration in Parkinson's disease.

Lactobacillus plantarum NK3 and Bifidobacterium longum NK49 regulate estrogen levels to prevent osteoporosis without increasing breast cancer risk.

Segmented epitope targeting blocks pathological seeding while sparing full-length tau.

GLP-1 receptor agonists reduce intracranial pressure by inhibiting sodium transport in the choroid plexus.

SCO-spondin-derived peptides enhance tight junction integrity between endothelial cells to maintain physiological barrier function.

A bifunctional fusion antibody transports GLB1 enzyme across the blood-brain barrier via receptor-mediated transcytosis.

CCR2-binding antibodies deplete monocytes, enabling late-stage intervention without aggravating immune responses or worsening arthritis symptoms.

Covalently bonding cyclic nitroxide radicals to hydrophobic block copolymers creates polymeric micelles that prevent rapid reduction by ascorbic acid.

Single Molecule Array detection of neurofilament light chain concentrations enables early identification of immunotherapy-associated neurotoxicity risks.

Optimized PLGA 75:25 microspheres deliver bupivacaine linearly over 28 days, resolving burst release issues in chronic pain management.

Liposomes encapsulate autoantigens within a phosphatidylserine membrane to induce tolerogenic presentation in antigen-presenting cells.

Centrifugal segmentation isolates platelet-derived serums with high cytokine concentrations, resolving slow preparation bottlenecks for emergency tissue repair.

Monovalent heterodimeric polypeptide extends serum half-life via FcRn binding while eliminating agonistic activity from TNF receptor targets.

Formula I kinase inhibitor crosses the blood-brain barrier, avoiding cardiovascular side effects of existing c-Abl inhibitors.

Chlorphenesin carbamate treats mood disorders by targeting skull tissue muscle tension, avoiding SSRI side effects like weight changes and dependency.

A folic compound combined with stabilizing heteroatom and conjugated segment antioxidants reduces neuropathic pain intensity.

Blautia strains reduce neurodevelopmental symptoms by modulating signaling molecules and gut permeability, resolving limited therapeutic characterization.

8-substituted guanine derivatives reduce blood pressure by promoting sodium excretion without increasing potassium loss or plasma glucose.

Water-soluble film transports anti-migraine agents through oral mucosa, bypassing gastrointestinal degradation to improve bioavailability.

Faecalibacterium prausnitzii-derived nanovesicles address diagnostic limitations by enabling multi-disease detection via PCR analysis of extracted DNA.

Prebiotic oligosaccharides shield lactoferrin from processing degradation to maintain biological activity.

Absorption enhancers facilitate CDNF and MANF transport across nasal mucosa, resolving unpredictable brain penetration for CNS disease treatment.

Chemical chaperones stabilize mutant beta-glucocerebrosidase, resolving high costs of enzyme replacement therapy for Gaucher's disease.

Purified cannabidiol with less than 0.1% THC treats KCNT1 mutation epilepsy, reducing seizures and improving development.

Decoction and ethanol extraction of TCM ingredients create a composition that relieves cancer pain while avoiding drug resistance and side effects.

Cyclodextrin derivatives form inclusion complexes with carbamate compounds, increasing aqueous solubility and storage stability without benzyl alcohol.

Segmented monoclonal antibodies bind distinct microtubule binding repeat domains to differentiate 3R and 4R tau isoforms for accurate diagnosis.

A pharmaceutical preparation with an inner layer composed of at least two diffusion layers featuring decreasing permeability from inside to outside.

NMDAR agonists enhance neurotransmission to mitigate psychiatric and cognitive symptoms while preventing relapses.

Muscle-derived progenitor cells expressing CD34 and Bcl-2 markers resolve low survival rates during skeletal muscle augmentation.

Differentiated MDMi cells replicate primary microglial function to screen neurodegenerative therapies without invasive tissue extraction.

Segmented CAIX binding polypeptides overcome poor tissue penetration of monoclonal antibodies to improve solid tumor targeting and diagnostic imaging.

Inhibiting hyaluronan synthesis with 4-methylumbelliferone resolves the contradiction between stable T-cell induction and immunosuppression.

Fn14/TRAIL fusion protein combines TWEAK and TRAIL receptor binding domains into a single therapeutic agent.

A gene delivery system uses an AAV vector paired with a UCHL1 promoter to express therapeutic proteins in specific neural populations.

Antibodies bind pathological beta-sheet conformations to treat amyloid diseases without inducing toxicity from conventional anti-Aβ therapies.

Selective antibody binding to amyloid beta 1-42 reduces neurofilament light chain levels, preventing neuronal axonal damage without harming amyloid beta 1-40.

An ethanol-resistant polymer coating maintains consistent drug release profiles despite gastric alcohol presence.

Pulicaria incisa infusion reduces oxidative stress and neuroinflammatory responses in astrocytes and microglia.